Bariatric surgery in patients with obesity and end-stage heart failure with left ventricular assist devices: a brief guide

Abstract

The prevalence of obesity is increasing worldwide, leading to a rise in several comorbidities, and is itself an important risk factor for heart failure. Patients with end-stage heart failure and obesity are often not eligible for heart transplantation (HT) and instead receive cardiac support from left ventricular assist devices (LVAD). In the absence of other contraindications, patients with obesity who are on LVAD support can lose enough weight to later qualify for HT. Bariatric surgery had been explored as an approach for weight loss in this patient population and was found to be a safe and effective option. One recent systematic review and meta-analysis has shown 67.4% of patients with LVAD support are able to be listed for transplantation after bariatric surgery and subsequent weight loss (95%CI: 0.477-0.871). Of these, 32.5% would go on to receive a heart transplant (95%CI: 0.201-0.448). There were also numerous cases of patients whose cardiac function improved after bariatric surgery such that they were delisted for HT and some had subsequent removal of their LVAD. There are many perioperative considerations when evaluating patients with LVADs for bariatric surgery. However, with careful patient selection by a multidisciplinary team and mindful preparation, patients with obesity and end-stage heart failure have an opportunity for longer years of life.

Keywords

Obesity / bariatric surgery / LVAD / left ventricular assist devices / heart failure / heart transplantation / laparoscopic sleeve gastrectomy / Roux-en-Y gastric bypass / review / surgical considerations

References

[1] Kivimäki M,Pentti J.Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study.Lancet Diabetes Endocrinol2022;10:253-63 PMCID:PMC8938400

[2] Kenchaiah S,Levy D.Obesity and the risk of heart failure.N Engl J Med2002;347:305-13

[3] Vest AR,Deswal A.Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the heart failure society of America scientific statements committee.J Card Fail2019;25:380-400

[4] Gómez-Ambrosi J,Rotellar F.Increased serum amyloid a concentrations in morbid obesity decrease after gastric bypass.Obes Surg2006;16:262-9

[5] Frühbeck G.The adipose tissue as a source of vasoactive factors.Curr Med Chem Cardiovasc Hematol Agents2004;2:197-208

[6] Russo MJ,Davies RR.The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines?.Ann Surg2010;251:144-52

[7] Fisher BW,Sultan I,Kilic A.Center-level variations in maximum recipient body mass index in heart transplantation.Am J Cardiol2021;145:91-6

[8] Foroutan F,Ross H.Impact of pretransplant recipient body mass index on post heart transplant mortality: a systematic review and meta-analysis.Clin Transplant2018;32:e13348

[9] Mehra MR, Canter CE, Hannan MM, et al; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases; Pediatric and Heart Failure and Transplantation Councils. The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1-23.

[10] Varshney AS,Cowger JA,Pinney SP.Trends and outcomes of left ventricular assist device therapy: JACC focus seminar.J Am Coll Cardiol2022;79:1092-107

[11] Vest AR,Rodgers JE.Obesity and weight loss strategies for patients with heart failure.JACC Heart Fail2024;12:1509-27

[12] McDowell K,Raihan NA.Effects of intentional weight loss in patients with obesity and heart failure: a systematic review.Obes Rev2018;19:1189-204

[13] Wickman BE,Ridberg R.Dietary management of heart failure: DASH diet and precision nutrition perspectives.Nutrients2021;13:4424 PMCID:PMC8708696

[14] Harrington J,Januzzi JL.Worth their weight? An update on new and emerging pharmacologic agents for obesity and their potential role for persons with cardiac conditions..Curr Cardiol Rep2024;26:61-71

[15] Wang JY,Yang XY.GLP-1 receptor agonists for the treatment of obesity: role as a promising approach.Front Endocrinol2023;14:1085799 PMCID:PMC9945324

[16] Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.

[17] Kosiborod MN, Petrie MC, Borlaug BA, et al; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394-407.

[18] Ussher JR.Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.Nat Rev Cardiol2023;20:463-74

[19] Benotti PN,Carey DJ.Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure.J Am Heart Assoc2017;6:e005126 PMCID:PMC5524077

[20] Persson CE,Lagergren J,Giang KW.Risk of heart failure in obese patients with and without bariatric surgery in sweden-a registry-based study.J Card Fail2017;23:530-7

[21] Hughes D,Tu C.Impact of bariatric surgery on left ventricular structure and function.J Am Heart Assoc2024;13:e031505 PMCID:PMC10863834

[22] daSilva-deAbreu A,Curbelo-Pena Y.Bariatric surgery in patients with obesity and ventricular assist devices considered for heart transplantation: systematic review and individual participant data meta-analysis.J Card Fail2021;27:338-48

[23] Sharma I,Hage K.Bariatric surgery and left ventricular assist device in patients with heart failure: a systematic review and meta-analysis.Am J Surg2023;226:340-9

[24] Orandi BJ,Cannon RM.Bariatric surgery to achieve transplant in end-stage organ disease patients: a systematic review and meta-analysis.Am J Surg2020;220:566-79 PMCID:PMC7484004

[25] Leviner DB,Ben-Gal T.Cardiac function recovery following LVAD implantation and bariatric surgery in a morbidly obese patient.J Card Surg2014;29:740-2

[26] Morrow EH,Mokadam NA.Laparoscopic gastric bypass during left ventricular assist device support and ventricular recovery.J Heart Lung Transplant2014;33:870-1

[27] Hawkins RB,Ayzengart A.Laparoscopic sleeve gastrectomy improves cardiac function for a heart failure patient requiring left ventricular assist device support.Surgery for Obesity and Related Diseases2018;14:S143

[28] Goldstein BA,Zaroff JG,Menza R.Assessment of heart transplant waitlist time and pre- and post-transplant failure: a mixed methods approach.Epidemiology2016;27:469-76 PMCID:PMC4892941

[29] Bakhtiyar SS,Ahmed S.Survival on the heart transplant waiting list.JAMA Cardiol2020;5:1227-35 PMCID:PMC7675100

[30] Chaudhry UI,Sai-Sudhakar CB,Needleman BJ.Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device: medium-term results.Surg Obes Relat Dis2015;11:88-93

[31] Lim CP,Falkenback D.Bariatric surgery provides a “bridge to transplant” for morbidly obese patients with advanced heart failure and may obviate the need for transplantation.Obes Surg2016;26:486-93

[32] Ristow B,Haeusslein E.Improvement in dilated cardiomyopathy after bariatric surgery.J Card Fail2008;14:198-202

[33] Samaras K,Lord RV,Hayward CS.Take heart: bariatric surgery in obese patients with severe heart failure. Two case reports.Heart Lung Circ2012;21:847-9

[34] Masarone D,Falco L.The ABC of heart transplantation-part 1: indication, eligibility, donor selection, and surgical technique.J Clin Med2023;12:5217 PMCID:PMC10455167

[35] daSilva-deAbreu A,Curbelo-Pena Y.Bariatric surgery in obese patients with ventricular assist devices.BMC Res Notes2020;13:382 PMCID:PMC7427728

[36] McElderry B,Hanna M.Outcomes of bariatric surgery in patients with left ventricular assist device.J Heart Lung Transplant2022;41:914-8

[37] Alsuhibani A,Wigle PR.Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network.Ann Surg Open2023;4:e317 PMCID:PMC10735086

[38] Jeng EI,Ahmed M.Left ventricular assist device and bariatric surgery: a bridge to heart transplant by weight and waiting time reduction.J Card Surg2016;31:120-2

[39] Dindo D,Clavien PA.Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann Surg2004;240:205-13 PMCID:PMC1360123

[40] Hwang KY.Facilitating noncardiac surgery for the patient with left ventricular assist device: a guide for the anesthesiologist.Ann Card Anaesth2018;21:351-62 PMCID:PMC6206808

[41] Stone M,Sattler C.Trends in the management of patients with left ventricular assist devices presenting for noncardiac surgery: a 10-year institutional experience.Semin Cardiothorac Vasc Anesth2016;20:197-204

[42] Amro A.A video case report of LRYGB in a patient with a left ventricular assist device.Surg Obes Relat Dis2015;11:1406-7

[43] Feldman D, Pamboukian SV, Teuteberg JJ, et al; International Society for Heart and Lung Transplantation. The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013;32:157-87.

[44] Strong AT,Nor Hanipah Z.Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy.Surg Obes Relat Dis2018;14:700-6